Introduction
Materials and methods
Results
Relapse rate (N = 857) | MRI activity (N = 765) | ||||
---|---|---|---|---|---|
Univariatea
| Multivariateb
| Univariatea
| Multivariateb
| ||
Predictors at baseline before treatment | |||||
Age |
−0.02 [−0.03, −0.01],
p = 0.002
|
−0.02 [−0.03, 0.00],
p = 0.011
|
−0.04 [−0.06, −0.02],
p < 0.0001
|
−0.04 [−0.05, −0.02],
p < 0.0001
| |
Male sex | −0.17 [−0.44, 0.10], p = 0.21 | – | 0.20 [−0.18, 0.59], p = 0.30 | – | |
Presence of Gd+ lesions |
0.26 [0.02, 0.50],
p = 0.032
| – |
0.83 [0.45, 1.21,],
p < 0.0001
| – | |
Baseline EDSS | 0.09 [−0.00, 0.19], p = 0.061 | – | 0.00 [−0.15, 0.15], p = 0.998 | – | |
Number of relapses in past 2 years |
0.25 [0.14, 0.37],
p < 0.0001
|
0.13 [0.02, 0.24],
p = 0.024
| 0.16 [−0.03, 0.35], p = 0.10 | – | |
Disease duration | −0.01 [−0.03, 0.01], p = 0.56 | – | −0.03 [−0.07, 0.01], p = 0.12 | – | |
Baseline T2 lesion volume |
0.01 [0.00, 0.02],
p = 0.005
| – |
0.02 [0.01, 0.03],
p = 0.001
|
0.01 [0.00, 0.02],
p = 0.011
| |
Black hole lesion volume |
0.03 [0.01, 0.06],
p = 0.017
| – | 0.03 [−0.01, 0.07], p = 0.18 | – | |
Predictors within 1 year of treatment | |||||
New MRI lesions in year 1 | 1–2 | −0.16 [−0.48, 0.16], p = 0.33 | −0.12 [−0.41, 0.17], p = 0.43 |
0.54 [0.07, 1.00],
p = 0.025
| 0.37 [−0.08, 0.82], p = 0.11 |
≥3 |
0.41 [0.13, 0.69],
p = 0.004
|
0.29 [0.02, 0.55],
p = 0.034
|
1.89 [1.52, 2.26],
p < 0.0001
|
1.51 [1.13, 1.88],
p < 0.0001
| |
NAb titer at year 1 | 20–400 | −0.06 [−0.34, 0.22], p = 0.67 | – |
0.90 [0.51, 1.28],
p < 0.0001
|
0.71 [0.40, 1.03],
p < 0.0001
|
>400 | −0.24 [−0.86, 0.38], p = 0.45 | – |
1.00 [0.36, 1.65],
p = 0.003
|
0.97 [0.45, 1.50],
p = 0.0003
| |
Confirmed EDSS progression in year 1 | 0.27 [−0.17, 0.72], p = 0.23 | – | −0.63 [−1.67, 0.41], p = 0.23 | – | |
Relapses in year 1 |
1.17 [0.94, 1.39],
p < 0.0001
|
1.03 [0.80, 1.26],
p < 0.0001
| 0.30 [−0.09, 0.68], p = 0.13 | – |